NM_000059.4:c.7633G>A
Variant summary
Our verdict is Uncertain significance. Variant got 0 ACMG points: 0P and 0B.
The NM_000059.4(BRCA2):c.7633G>A(p.Val2545Ile) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00000558 in 1,612,614 control chromosomes in the GnomAD database, with no homozygous occurrence. 11/19 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_000059.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Uncertain_significance. Variant got 0 ACMG points.
Transcripts
RefSeq
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
BRCA2 | ENST00000380152.8 | c.7633G>A | p.Val2545Ile | missense_variant | Exon 16 of 27 | 5 | NM_000059.4 | ENSP00000369497.3 | ||
BRCA2 | ENST00000530893.7 | c.7264G>A | p.Val2422Ile | missense_variant | Exon 16 of 27 | 1 | ENSP00000499438.2 | |||
BRCA2 | ENST00000614259.2 | n.7633G>A | non_coding_transcript_exon_variant | Exon 15 of 26 | 2 | ENSP00000506251.1 |
Frequencies
GnomAD3 genomes AF: 0.0000132 AC: 2AN: 152048Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.00000399 AC: 1AN: 250892Hom.: 0 AF XY: 0.00 AC XY: 0AN XY: 135652
GnomAD4 exome AF: 0.00000479 AC: 7AN: 1460566Hom.: 0 Cov.: 31 AF XY: 0.00000138 AC XY: 1AN XY: 726640
GnomAD4 genome AF: 0.0000132 AC: 2AN: 152048Hom.: 0 Cov.: 32 AF XY: 0.0000135 AC XY: 1AN XY: 74250
ClinVar
Submissions by phenotype
not provided Uncertain:3
This variant is denoted BRCA2 c.7633G>A at the cDNA level, p.Val2545Ile (V2545I) at the protein level, and results in the change of a Valine to an Isoleucine (GTT>ATT). Using alternate nomenclature, this variant would be defined as BRCA2 7861G>A. This variant has not, to our knowledge, been published in the literature as a pathogenic or benign germline variant. BRCA2 Val2545Ile was not observed at a significant allele frequency in large population cohorts (Lek 2016). This variant is located in the DNA binding domain and the FANCD2 binding domain (Yang 2002). In silico analysis, which includes protein predictors and evolutionary conservation, supports that this variant does not alter protein structure/function. Based on currently available evidence, it is unclear whether BRCA2 Val2545Ile is a pathogenic or benign variant. We consider it to be a variant of uncertain significance. -
- -
- -
Breast-ovarian cancer, familial, susceptibility to, 2 Uncertain:2
- -
- -
Hereditary cancer-predisposing syndrome Uncertain:2
- -
The p.V2545I variant (also known as c.7633G>A), located in coding exon 15 of the BRCA2 gene, results from a G to A substitution at nucleotide position 7633. The valine at codon 2545 is replaced by isoleucine, an amino acid with highly similar properties. This alteration was detected in a set of high-risk families with suspected hereditary breast and ovarian cancer and was found to have no effect on RNA splicing (Menéndez M et al. Breast Cancer Res. Treat. 2012 Apr;132:979-92). This amino acid position is well conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. -
Familial cancer of breast Uncertain:1Benign:1
- -
ACMG codes applied following ENIGMA VCEP rules: BS2_SUP, BP5_MOD, BP4 -
BRCA2-related cancer predisposition Uncertain:1
This missense variant replaces valine with isoleucine at codon 2545 of the BRCA2 protein. Computational prediction suggests that this variant may not impact protein structure and function. To our knowledge, functional studies have not been reported for this variant. This variant has been reported in a suspected hereditary breast and ovarian cancer family (PMID: 21735045) and in a multifactorial analysis with tumor pathology, co-occurrence and family history likelihood ratios for pathogenicity of 0.33, 1.050 and 0.397, respectively (PMID: 31131967). This variant has been identified in 2/282264 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. -
Hereditary breast ovarian cancer syndrome Uncertain:1
This sequence change replaces valine, which is neutral and non-polar, with isoleucine, which is neutral and non-polar, at codon 2545 of the BRCA2 protein (p.Val2545Ile). This variant is present in population databases (rs80358990, gnomAD 0.004%). This missense change has been observed in individual(s) with hereditary breast and/or ovarian cancer (HBOC) (PMID: 19043619, 21735045, 35534704). ClinVar contains an entry for this variant (Variation ID: 52374). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is not expected to disrupt BRCA2 protein function with a negative predictive value of 95%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at